CJ Bioscience. Inc.

CJ Bioscience. Inc.

KKRX:311690
3,495.00
KRW
-50.00
(-1.41%)
-1,708.76EPS
56.97BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
870.53
1,004.68
1,071.31
1,271.18
1,206.64
899.92
607.92
787.13
373.81
282.57
281.42
Basic EPS, GAAP
-751.52
-647.17
-855.88
-1,154.91
-1,990.62
-3,975.1
-5,208.94
-3,235
-3,541
-1,837
-1,708.76
Free Cash Flow per Basic Share
-726.27
-723.52
-598.38
-786.51
-6,098.34
-1,942.14
-3,854.22
-5,833.21
-3,056.4
-1,797.76
-1,517.94
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3,530.59
3,040.67
2,489.65
7,103.59
7,769.08
13,116.25
7,407.13
7,845.89
5,951.3
4,105.42
3,195.1
Tangible Book Value per Share
3,516.19
3,016.04
2,460.63
7,074.56
7,745.66
13,099.22
7,255.59
6,485.4
4,994.63
3,203.95
2,295.81
Basic Weighted Avg Shares
3
4
4
4
4
5
7
7
9
13
13
Sales/Revenue/Turnover
2,996
3,668
3,924
4,783
5,312
4,363
4,075
5,575
3,467
3,693
3,677
Operating Margin (%)
-72.84
-70.34
-86.81
-94.47
-160.79
-231.68
-815.1
-575
-987.76
-671.24
-624.86
Depreciation Expense
609
516
461
731
1,051
1,562
3,900
5,146
4,321
4,013
3,824
Net Income, GAAP
-2,587
-2,363
-3,135
-4,346
-8,763
-19,272
-34,913
-22,913
-32,838
-24,005
-22,327
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-86.33
-64.42
-79.89
-90.85
-164.97
-441.72
-856.84
-410.99
-947.28
-650.1
-607.2
Working Capital
14,282
11,197
9,585
29,337
38,085
57,718
15,953
50,488
58,236
37,920
27,949
LT Debt
- -
- -
- -
368
35,560
4,088
3,831
2,692
1,162
1,495
- -
Total Equity
15,283
13,163
10,777
30,855
34,484
87,853
49,655
71,496
77,757
53,639
41,745
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-16.61
-26.19
-20.88
-26.82
-31.51
-50.78
-37.83
-44
-36.54
-41.76

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,916
9,387
7,882
LT Borrowings
- -
- -
- -
LT Finance Leases
1,495
1,225
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
121,770
102,172
56,965

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
52,478
46,094
42,800
Cash, Cash Equivalents & STI
50,839
44,130
40,951
Accounts Receivable, Net
419
230
- -
Inventories
185
258
242
Total Current Liabilities
14,558
13,034
14,851
Payables & Accruals
- -
- -
- -
ST Debt
8,916
9,387
7,882
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.6%
-31.02%
Free Cash Flow
- -
24.17%
-17.12%
Net Income, GAAP
- -
36.63%
-26.9%
Sales/Revenue/Turnover
- -
-3.79%
6.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,004
777
744
941
3,467
2025
913
784
738
1,258
3,693
2026
783
898
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-809.28
-848
-907
-976.47
-3,541
2025
-469.08
-527
-446.12
-395.16
-1,837
2026
-392.46
-475
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Full Time Employees
102
Sector
Technology services
Industry
Data processing services
Address
Seoul South Korea
IPO Date
Dec 26, 2019
Business
CJ Bioscience, Inc. is a South Korea-based biotechnology and bioinformatics company specializing in microbiome-based genomics, digital healthcare analytics, and precision wellness solutions. Operating as a dedicated red biotechnology subsidiary of CJ CheilJedang within the CJ Group, the company provides comprehensive bioinformatics tools, sequencing services, and diagnostic systems to academic institutions, clinical laboratories, pharmaceutical enterprises, and individual consumers globally. The company categorizes its primary business operations across specialized research services, bioinformatics platforms, and health diagnostics, offering: EzBioCloud, a proprietary cloud-based microbial taxonomic identification database and bioinformatics analytics platform utilized by researchers internationally; Next-Generation Sequencing (NGS) and multi-omics analytical services, including Microbiome Taxonomic Profiling (MTP), shotgun metagenomics, bacterial whole-genome sequencing, comparative genomics, and RNA sequencing; TrueBac ID, an automated genome-based bacterial identification and pathogen diagnostic system; Gut Inside, a clinical-grade gut microbiome profiling and Gut Microbiome Index (GMI) testing service distributed through hospitals and healthcare clinics; SMILE GUT, a direct-to-consumer gut microbiome home testing kit providing personalized lifestyle insights; and Ez-Mx, an artificial intelligence-driven data platform developed for microbial strain screening and biomarker discovery. Founded in 2009 as ChunLab, Inc. and headquartered in Seoul, South Korea, the company was acquired by CJ CheilJedang in 2021 and officially reorganized and renamed as CJ Bioscience, Inc. in January 2022. In major strategic developments, the company acquired 11 microbiome therapeutic candidates, patents, and intellectual property assets from UK-based 4D pharma plc in 2023 to expand its therapeutic pipeline. More recently, the company executed a strategic corporate reorganization to prioritize commercial business units and immediate cash-flow generation, refocusing resources on bioinformatics software services, health-functional foods, precision nutrition, and clinical diagnostic partnerships, such as a strategic healthcare cooperation agreement with Sun Medical Center, following the voluntary discontinuation of its Phase 1 immuno-oncology drug candidate CJRB-101.